Etoricoxib and the treatment of ankylosing spondylitis

Bibliography

• Dougados M, Baeten D. Spondyloarthritis. Lancet 2011;Jun18377(9783):2127-37
   PubMed Web of Science ®Google Scholar
• Baeten D, Breban M, Lories R, Spondyloarthritides: related but distinct conditions or a single disease with a heterogeneous phenotype? Arthritis Rheum 2012; doi: 10.1002/art.34627
   Web of Science ®Google Scholar
• Saraux A, Guillemin F, Guggenbuhl P, Prevalence of spondyloarthropathies in France: 2001. Ann Rheum Dis 2005;64(10):1431-5
   PubMed Web of Science ®Google Scholar
• Helmick CG, Felson DT, Lawrence RC, Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008;Jan58(1):15-25
   PubMed Web of Science ®Google Scholar
• Thomas GP, Brown MA. Genetics and genomics of ankylosing spondylitis. Immunol Rev 2010;Jan233(1):162-80
   PubMedGoogle Scholar
• Boonen A, Brinkhuizen T, Landewe R, Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity, and estimation of the societal cost. Ann Rheum Dis 2010;Jun69(6):1123-8
   PubMed Web of Science ®Google Scholar
• Machado P, Landewe R, Braun J, Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Ann Rheum Dis 2010;Aug69(8):1465-70
   PubMed Web of Science ®Google Scholar
• Braun J, Pincus T. Mortality, course of disease and prognosis of patients with ankylosing spondylitis. Clin Exp Rheumatol 2002;Nov-Dec20(6 Suppl 28):S16-22
   PubMed Web of Science ®Google Scholar
• Wanders A, Heijde D, Landewe R, Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005;Jun52(6):1756-65
   PubMed Web of Science ®Google Scholar
• Kroon F, Landewe R, Dougados M, van der Heijde D. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis 2012;71(10):1623-9
   PubMed Web of Science ®Google Scholar
• Poddubnyy D, Rudwaleit M, Haibel H, Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis 2012;71(10):1616-22
   PubMed Web of Science ®Google Scholar
• Lories RJ, de Vlam K, Luyten FP. Are current available therapies disease-modifying in spondyloarthritis? Best Pract Res Clin Rheumatol 2010;Oct24(5):625-35
   PubMed Web of Science ®Google Scholar
• Amor B, Dougados M, Mijiyawa M. Criteria of the classification of spondylarthropathies. Rev Rhum Mal Osteoartic 1990;Feb57(2):85-9
   PubMedGoogle Scholar
• Sieper J, Rudwaleit M, Baraliakos X, The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009;68(Suppl 2):ii1-44
   PubMed Web of Science ®Google Scholar
• Schaible HG, Richter F, Ebersberger A, Joint pain. Exp Brain Res 2009;Jun196(1):153-62
   PubMed Web of Science ®Google Scholar
• Amor B, Dougados M, Listrat V, Are classification criteria for spondylarthropathy useful as diagnostic criteria? Rev Rhum Engl Ed 1995;Jan62(1):10-15
   PubMedGoogle Scholar
• Van Praet L, Van den Bosch F, Mielants H, Elewaut D. Mucosal inflammation in spondylarthritides: past, present, and future. Curr Rheumatol Rep 2011;Oct13(5):409-15
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, Higuchi LM, Huang ES, Aspirin, nonsteroidal anti-inflammatory drug use, and risk for Crohn disease and ulcerative colitis: a cohort study. Ann Intern Med 2012;Mar6156(5):350-9
   PubMed Web of Science ®Google Scholar
• Trelle S, Reichenbach S, Wandel S, Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011;342:c7086
   PubMed Web of Science ®Google Scholar
• Botting RM. Inhibitors of cyclooxygenases: mechanisms, selectivity and uses. J Physiol Pharmacol 2006;Nov57(Suppl 5):113-24
   PubMed Web of Science ®Google Scholar
• Riendeau D, Percival MD, Brideau C, Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001;Feb296(2):558-66
   PubMed Web of Science ®Google Scholar
• Dallob A, Hawkey CJ, Greenberg H, Characterization of etoricoxib, a novel, selective COX-2 inhibitor. J Clin Pharmacol 2003;Jun43(6):573-85
   PubMed Web of Science ®Google Scholar
• Schwartz JI, Dallob AL, Larson PJ, Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects. J Clin Pharmacol 2008;Jun48(6):745-54
   PubMed Web of Science ®Google Scholar
• Agrawal NG, Porras AG, Matthews CZ, Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase-2 inhibitor, in healthy volunteers. J Clin Pharmacol 2001;Oct41(10):1106-10
   PubMed Web of Science ®Google Scholar
• Agrawal NG, Porras AG, Matthews CZ, Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man. J Clin Pharmacol 2003;Mar43(3):268-76
   PubMed Web of Science ®Google Scholar
• Schwartz JI, Agrawal NG, Kher UA, Lack of effect of antacids on single-dose pharmacokinetics of etoricoxib. J Clin Pharmacol 2007;Oct47(10):1342-6
   PubMed Web of Science ®Google Scholar
• Rodrigues AD, Halpin RA, Geer LA, Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers. Drug Metab Dispos 2003;Feb31(2):224-32
   PubMed Web of Science ®Google Scholar
• Chauret N, Yergey JA, Brideau C, In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663). Bioorg Med Chem Lett 2001;Apr2311(8):1059-62
   PubMed Web of Science ®Google Scholar
• Kassahun K, McIntosh IS, Shou M, Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor. Drug Metab Dispos 2001;Jun29(6):813-20
   PubMed Web of Science ®Google Scholar
• Agrawal NG, Matthews CZ, Mazenko RS, The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activity. J Clin Pharmacol 2004;Oct44(10):1125-31
   PubMed Web of Science ®Google Scholar
• Agrawal NG, Matthews CZ, Mazenko RS, Pharmacokinetics of etoricoxib in patients with renal impairment. J Clin Pharmacol 2004;Jan44(1):48-58
   PubMed Web of Science ®Google Scholar
• Agrawal NG, Rose MJ, Matthews CZ, Pharmacokinetics of etoricoxib in patients with hepatic impairment. J Clin Pharmacol 2003;Oct43(10):1136-48
   PubMed Web of Science ®Google Scholar
• Schwartz JI, Agrawal NG, Hartford AH, The effect of etoricoxib on the pharmacodynamics and pharmacokinetics of warfarin. J Clin Pharmacol 2007;May47(5):620-7
   PubMed Web of Science ®Google Scholar
• Schwartz JI, Agrawal NG, Wong PH, Examination of the effect of increasing doses of etoricoxib on oral methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Clin Pharmacol 2009;49(10):1202-9
   PubMed Web of Science ®Google Scholar
• Schwartz J, Hunt T, Smith WB, The effect of etoricoxib on the pharmacokinetics of oral contraceptives in healthy participants. J Clin Pharmacol 2009;Jul49(7):807-15
   PubMed Web of Science ®Google Scholar
• Schwartz JI, Agrawal NG, Wehling M, Evaluation of the pharmacokinetics of digoxin in healthy subjects receiving etoricoxib. Br J Clin Pharmacol 2008;Dec66(6):811-17
   PubMed Web of Science ®Google Scholar
• Capone ML, Tacconelli S, Patrignani P. Clinical pharmacology of etoricoxib. Expert Opin Drug Metab Toxicol 2005;Aug1(2):269-82
   PubMedGoogle Scholar
• van der Heijde D, Baraf HS, Ramos-Remus C, Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 2005;Apr52(4):1205-15
   PubMed Web of Science ®Google Scholar
• Gossec L, van der Heijde D, Melian A, Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis. Ann Rheum Dis 2005;Nov64(11):1563-7
   PubMed Web of Science ®Google Scholar
• Jansen JP, Gaugris S, Choy EH, Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis. Pharmacoeconomics 2010;28(4):323-44
   PubMed Web of Science ®Google Scholar
• Jarrett SJ, Sivera F, Cawkwell LS, MRI and clinical findings in patients with ankylosing spondylitis eligible for anti-tumour necrosis factor therapy after a short course of etoricoxib. Ann Rheum Dis 2009;Sep68(9):1466-9
   PubMed Web of Science ®Google Scholar
• Garcia Rodriguez LA, Barreales Tolosa L. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology 2007;Feb132(2):498-506
   PubMed Web of Science ®Google Scholar
• Hunt RH, Harper S, Watson DJ, The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 2003;Aug98(8):1725-33
   PubMed Web of Science ®Google Scholar
• Laine L, Curtis SP, Cryer B, Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007;Feb10369(9560):465-73
   PubMed Web of Science ®Google Scholar
• Combe B, Swergold G, McLay J, Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). Rheumatology (Oxford) 2009;Apr48(4):425-32
   PubMed Web of Science ®Google Scholar
• Baraf HS, Fuentealba C, Greenwald M, Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial. J Rheumatol 2007;Feb34(2):408-20
   PubMed Web of Science ®Google Scholar
• Krueger K, Lino L, Dore R, Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II). Ann Rheum Dis 2008;Mar67(3):315-22
   PubMed Web of Science ®Google Scholar
• McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 2011;Sep8(9):e1001098
   PubMed Web of Science ®Google Scholar
• Haag MD, Bos MJ, Hofman A, Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke. Arch Intern Med 2008;Jun9168(11):1219-24
   PubMed Web of Science ®Google Scholar
• Chan CC, Reid CM, Aw TJ, Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J Hypertens 2009;Dec27(12):2332-41
   PubMed Web of Science ®Google Scholar
• Krum H, Curtis SP, Kaur A, Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program. Eur J Heart Fail 2009;Jun11(6):542-50
   PubMed Web of Science ®Google Scholar
• Nurmohamed MT, van der Horst-Bruinsma I, Maksymowych WP. Cardiovascular and cerebrovascular diseases in ankylosing spondylitis: current insights. Curr Rheumatol Rep 2012;14(5):415-21
   PubMedGoogle Scholar
• Viola M, Quaratino D, Gaeta F, Etoricoxib tolerability in patients with hypersensitivity to nonsteroidal anti-inflammatory drugs. Int Arch Allergy Immunol 2007;143(2):103-8
   PubMed Web of Science ®Google Scholar
• Asero R. Etoricoxib challenge in patients with chronic urticaria with NSAID intolerance. Clin Exp Dermatol 2007;Nov32(6):661-3
   PubMed Web of Science ®Google Scholar
• Muratore L, Ventura M, Calogiuri G, Tolerance to etoricoxib in 37 patients with urticaria and angioedema induced by nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2007;Feb98(2):168-71
   PubMed Web of Science ®Google Scholar
• El Miedany Y, Youssef S, Ahmed I, El Gaafary M. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol 2006;Feb101(2):311-17
   PubMed Web of Science ®Google Scholar
• Miao X, Ouyang Q, Li H, Role of selective cyclooxygenase-2 inhibitors in exacerbation of inflammatory bowel disease: a systematic review and meta-analysis Curr Ther Res. 2008;69(3):181-91
   Google Scholar